Type 2 Diabetes

The patient is new to you, he's got type 2 DM and has a lot of meds on board. There's danger in this mix. Read the history and see if you spot the problem.

Researchers have shown that testosterone replacement therapy reduces the complications associated with type 2 diabetes mellitus in androgen-deficient, overweight men.

Endocrinologists generally see middle-aged people who have developed type 2 diabetes mellitus (T2DM) subsequent to overnutrition (or overeating) and weight gain. Most clinicians tend to forget that low caloric intake, or undernutrition, in the prenatal period or during a child's formative years also seems to increase the risk of the T2DM later in life.

After sleeve gastrectomy, obese patients with type 2 DM who have less severe disease do better than those who have more advanced disease. Surgery should be encouraged sooner rather than later.

Some of the reasons cited for the observed cost efficiencies: better achievement of A1C and composite quality-of-care goals and fewer treatment failures.

The need for diabetes and cardiac medications is reduced significantly in obese patients who undergo weight-loss surgery, and so are their costs.

In patients with A1c poorly controlled on metformin, dual add-on therapy with saxagliptin plus dapagliflozin brought more to A1c goals than either drug added alone.

Among diabetics, poor adherence or nonadherence results in poorer glycemic control and increased risk of complications and disability, as well as increased healthcare costs.

Despite achieving optimal goals for "bad" cholesterol levels, individuals with diabetes and chronic kidney disease still have an elevated risk of vascular complications.

Until now, the USPSTF has recommended against screening asymptomatic adults for diabetes. A recent draft recommendation shifts focus and suggests intermittent screening for certain high-risk adults.

Low testosterone is a common condition among men with diabetes-diabetic men are approximately twice as likely as others to develop low testosterone and hypogonadism. Because its symptoms mimic other conditions, patients often fail to report concerns and clinicians may fail to diagnose "Low T."

Retching, bloating, abdominal pain, early fullness...which is worse in patients with "diabetic stomach"?

Clue: What do domperidone and metoclopramide have in common?

A new study found the 30-day complication rate associated with laparoscopic Roux-en-Y gastric bypass to be 3.4%-about the same as with laparascopic cholecystectomy and appendectomy.

Patients with type 1 diabetes could get much needed help from an unlikely source if positive results from animal model tests with a common diabetes drug can be replicated in clinical trials with humans.

For individuals with type 2 diabetes mellitus, a low carbohydrate, low saturated fat diet in combination with exercise resulted in superior glycemic control with less medication use than did a higher carbohydrate diet

Pediatric obesity is increasing in prevalence, with severe childhood obesity being seen more and more frequently.

There is currently no algorithm to guide clinicians in deciding which medication to choose to help promote weight loss in individuals with obesity. Rather, clinicians must take stock of a variety of factors when making treatment decisions for a particular patient.

The range of medication choices to treat obesity is expanding, and a rational prescribing plan requires a solid grasp of medication side effects.

Using a variety of cognitive strategies may help dampen food cravings and boost inhibitory control in individuals with obesity, according to a small neuroimaging study that draws methods from addiction research.

An intragastric dual-balloon device was well tolerated and proved effective for patients with moderate levels of obesity, owing in part to its ability to conform to stomach anatomy, according to Jaime Ponce, MD, Medical Director for the Bariatric Surgery program at Hamilton Medical Center, in Dalton, Georgia.

Hypoglycemia was common among study participants but those who received dapagliflozin had reductions in daily average serum glucose levels, glycemic variability, and percent change in total daily insulin dose.

If almost everyone with necrobiosis lipoidica has diabetes mellitus, does almost everyone with diabetes mellitus have necrobiosis lipoidica?

The SGLT2 inhibitor in clinical trials was associated with decreases in systolic blood pressure. The current study looked specifically at the drug's effect on blood pressure--with encouraging results.

Low total serum testosterone was independently associated with greater carotid intima media thickening and endothelial dysfunction but not with atherosclerotic plaques.

As the number of bariatric surgeries increase, clinicians require more and better data about its long-term outcomes. As we know, as more people take a medication or undergo a surgical procedure, the better the quality of the collective data. It's the strength in numbers concept. In the case of bariatric surgery, many clinicians have questions about treatment failure rates and they suspect that reports of sustained weight loss may be overly optimistic.

Looking at patients with asthma it can be easy to group them all together for treatment options. Recent studies have shown that that may not be the best way to approach helping people dealing with both obesity and asthma.

Symptoms of diabetic gastroparesis include nausea, vomiting, early satiety, and bloating. Where should management start?

AstraZeneca today announced that the US Food and Drug Administration has approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes mellitus.

The 2013 revision of guidelines on managing overweight and obesity in adults suggests that providers and patients set a goal of a sustained weight loss of 3-5% of baseline body weight to obtain improvements in triglycerides, blood glucose, HbA1c, and the risk of developing type 2 diabetes mellitus.